This is an audio version of the Wikipedia Article: Encenicline Listening is a more natural way of learning, when compared to reading. Written language only began at around 3200 BC, but spoken language has existed long ago. Learning by listening is a great way to: - increases imagination and understanding - improves your listening skills - improves your own spoken accent - learn while on the move - reduce eye strain Now learn the vast amount of general knowledge available on Wikipedia through audio (audio article). You could even learn subconsciously by playing the audio while you are sleeping! If you are planning to listen a lot, you could try using a bone conduction headphone, or a standard speaker instead of an earphone. You can find other Wikipedia audio articles too at: https://www.youtube.com/channel/UCuKfABj2eGyjH3ntPxp4YeQ In case you don't find one that you were looking for, put a comment. This video uses Google TTS en-US-Standard-D voice. SUMMARY ======= Encenicline (INN, USAN, code names EVP-6124, MT-4666) is a selective partial agonist of the α7 nicotinic receptor, and is in phase III clinical trials for the treatment of cognitive impairment in schizophrenia.FORUM Pharmaceuticals, who currently is subjecting the drug to the FDA approval process, had all studies suspended until further notice in fall of 2015 due to rare, but serious gastrointestinal problems occurring in patients participating in the drug trial, potentially being a consequence of taking the drug. The trials were scheduled to be run until January 2017, but as of December 2016, they appear to still be on hold. There is speculation by FORUM Pharmaceuticals that this may be due to either the increased daily dose given in the phase III trial compared to earlier trials that showed promise. In previous trials, the highest dose given was 2 mg/day, with the most positive of effects having been realized in patients taking the largest dose (2 mg/day). In the phase III trial, all patients were treated with 3 mg/day doses of the drug. FORUM also speculates that the increase of gastrointestinal problems occurring in the phase III trial could be due to the increased demographic risk that elderly (the average age in the study was 75) and those with Alzheimer's disease have in regard to gastrointestinal issues, citing another study they conducted with a younger demographic (in which the average age was 35–40) for the treatment of schizophrenia of 1,500 individuals in which there were zero complains of gastrointestinal problems.

• published: 28 Oct 2018
• views: 12